UY25114A1 - Derivados orto-sustituidos de la hidroxicumaranona como agentes antitumorales y antimetastásicos. - Google Patents
Derivados orto-sustituidos de la hidroxicumaranona como agentes antitumorales y antimetastásicos.Info
- Publication number
- UY25114A1 UY25114A1 UY25114A UY25114A UY25114A1 UY 25114 A1 UY25114 A1 UY 25114A1 UY 25114 A UY25114 A UY 25114A UY 25114 A UY25114 A UY 25114A UY 25114 A1 UY25114 A1 UY 25114A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formula
- compounds
- agents
- hydroxicumaranone
- antimetastasic
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- YXVNSYLJLOZDBQ-UHFFFAOYSA-N 3h-benzo[g][1]benzofuran-2-one Chemical class C1=CC=CC2=C(OC(=O)C3)C3=CC=C21 YXVNSYLJLOZDBQ-UHFFFAOYSA-N 0.000 abstract 1
- IQRBPUVIUQDULO-UHFFFAOYSA-N 4-fluoro-n-piperidin-4-ylbenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1CCNCC1 IQRBPUVIUQDULO-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 abstract 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000002257 antimetastatic agent Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004427 diamine group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000005504 styryl group Chemical group 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Abstract
Se describe una benzocumaranona hidroxi substituida de fórmula general (I): en donde R, R', están independientemente entre si, seleccionados entre H, alquilo, estirilo y cicloalquilo, o tomados conjuntamente con el carbono al cual están unidos, forman un grupo cicloalquilo; A esta seleccioando entre los grupo siguientes: (CH2)n, CH2CH=CHCH2, CH2-CH2-CH2, CH2-CHOH-CHOH-CH2, etc; B es N(R1)-(CH2)m-N(R2)- o compuestos de fórmula ll y T significa CH2-C=CH, C=CH, (CH2)p-O-R3, CH=CH-R3, etc y x es 0 ó 1. En particular, B es un radical diamina, piperazina o piperidina. Se describe también el empleo de los compuestos de fórmula (I) (como por ejemplo: 4-(4-(4-(4-fluorobenzamido)piperidin)butoxi)-2-isopropilidencumaran-3-ona) como inhibidores de la unión de uPA al receptor específico uPAR y en particular, su aplicación como agentes antitumorales y antimetastásicos. Composiciones farmacéuticas que contienen una cantidad eficaz de uno o más compuestos de fórmula l, en mezcla con excipientes farmacéuticamente eficaces y/o diluyentes
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97113190 | 1997-07-31 | ||
| EP98106946 | 1998-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25114A1 true UY25114A1 (es) | 2001-01-31 |
Family
ID=26145681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25114A UY25114A1 (es) | 1997-07-31 | 1998-07-29 | Derivados orto-sustituidos de la hidroxicumaranona como agentes antitumorales y antimetastásicos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6200989B1 (es) |
| EP (1) | EP1012147B1 (es) |
| JP (1) | JP3241711B2 (es) |
| KR (1) | KR100343067B1 (es) |
| AR (1) | AR013374A1 (es) |
| AT (1) | ATE308535T1 (es) |
| AU (1) | AU745839B2 (es) |
| BR (1) | BR9811589A (es) |
| CA (1) | CA2296476A1 (es) |
| DE (1) | DE69832184D1 (es) |
| HR (1) | HRP20000031A2 (es) |
| HU (1) | HUP0004221A2 (es) |
| ID (1) | ID24525A (es) |
| IL (1) | IL134193A0 (es) |
| MA (1) | MA26528A1 (es) |
| NO (1) | NO20000366D0 (es) |
| PE (1) | PE106099A1 (es) |
| PL (1) | PL338614A1 (es) |
| TR (1) | TR200000272T2 (es) |
| UY (1) | UY25114A1 (es) |
| WO (1) | WO1999006387A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU736869B2 (en) * | 1999-01-30 | 2001-08-02 | Roche Diagnostics Gmbh | O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents |
| AU2002362030A1 (en) * | 2001-11-27 | 2003-06-10 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| WO2003051347A1 (en) * | 2001-12-19 | 2003-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of urokinase receptor antagonists to modulate ischemiareperfusion injury |
| WO2004076444A2 (en) * | 2003-02-25 | 2004-09-10 | F. Hoffmann-La Roche Ag | Novel hydroxycoumaranone derivatives as antitumor and antimetastatic |
| EP2077260B1 (en) * | 2006-10-27 | 2015-02-18 | The University of Tokyo | Amide compound or salt thereof, and biofilm formation inhibitor, biofilm remover and bactericide each using the amide compound or salt thereof |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| GB2462022B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| PT109740B (pt) | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
| CA3068254A1 (en) | 2017-06-20 | 2018-12-27 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| KR20200094734A (ko) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 헤테로사이클릭 화합물 |
| DK3697785T3 (da) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidazo-pyridine forbindelser som pad-inhibitorer |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| CA3083374A1 (en) | 2017-11-24 | 2019-05-31 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
| JP2021508336A (ja) | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| AU2019234185A1 (en) | 2018-03-13 | 2020-10-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
| EP3801522A4 (en) * | 2018-06-05 | 2022-06-01 | Praxis Biotech LLC | INTEGRATED STRESS RESPONSE PATHWAY INHIBITORS |
| EP3982965A4 (en) | 2019-06-12 | 2023-01-25 | Praxis Biotech LLC | INTEGRATED STRESS RESPONSE PATHWAY MODULATORS |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2901336A1 (de) | 1979-01-15 | 1980-07-24 | Boehringer Mannheim Gmbh | Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3209271A1 (de) * | 1982-03-13 | 1983-09-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3587711T2 (de) * | 1984-08-13 | 1994-04-28 | Biotech Australia Pty Ltd | Minaktivin. |
| US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
-
1998
- 1998-07-23 PL PL98338614A patent/PL338614A1/xx not_active Application Discontinuation
- 1998-07-23 BR BR9811589-8A patent/BR9811589A/pt not_active Application Discontinuation
- 1998-07-23 IL IL13419398A patent/IL134193A0/xx unknown
- 1998-07-23 AU AU91559/98A patent/AU745839B2/en not_active Ceased
- 1998-07-23 JP JP2000505146A patent/JP3241711B2/ja not_active Expired - Fee Related
- 1998-07-23 AT AT98943771T patent/ATE308535T1/de not_active IP Right Cessation
- 1998-07-23 CA CA002296476A patent/CA2296476A1/en not_active Abandoned
- 1998-07-23 HU HU0004221A patent/HUP0004221A2/hu unknown
- 1998-07-23 KR KR1020007000941A patent/KR100343067B1/ko not_active IP Right Cessation
- 1998-07-23 WO PCT/EP1998/004619 patent/WO1999006387A2/en not_active Application Discontinuation
- 1998-07-23 TR TR2000/00272T patent/TR200000272T2/xx unknown
- 1998-07-23 DE DE69832184T patent/DE69832184D1/de not_active Expired - Lifetime
- 1998-07-23 EP EP98943771A patent/EP1012147B1/en not_active Expired - Lifetime
- 1998-07-23 ID IDW20000173A patent/ID24525A/id unknown
- 1998-07-29 AR ARP980103732A patent/AR013374A1/es unknown
- 1998-07-29 UY UY25114A patent/UY25114A1/es not_active Application Discontinuation
- 1998-07-30 PE PE1998000679A patent/PE106099A1/es not_active Application Discontinuation
- 1998-07-31 MA MA25200A patent/MA26528A1/fr unknown
-
1999
- 1999-09-22 US US09/401,403 patent/US6200989B1/en not_active Expired - Fee Related
-
2000
- 2000-01-20 HR HR20000031A patent/HRP20000031A2/hr not_active Application Discontinuation
- 2000-01-25 NO NO20000366A patent/NO20000366D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL338614A1 (en) | 2000-11-06 |
| MA26528A1 (fr) | 2004-12-20 |
| DE69832184D1 (de) | 2005-12-08 |
| ID24525A (id) | 2000-07-20 |
| AR013374A1 (es) | 2000-12-27 |
| AU9155998A (en) | 1999-02-22 |
| US6200989B1 (en) | 2001-03-13 |
| HUP0004221A2 (hu) | 2001-04-28 |
| BR9811589A (pt) | 2000-09-19 |
| CA2296476A1 (en) | 1999-02-11 |
| JP3241711B2 (ja) | 2001-12-25 |
| AU745839B2 (en) | 2002-04-11 |
| NO20000366L (no) | 2000-01-25 |
| EP1012147A2 (en) | 2000-06-28 |
| JP2001512113A (ja) | 2001-08-21 |
| PE106099A1 (es) | 1999-11-11 |
| NO20000366D0 (no) | 2000-01-25 |
| ATE308535T1 (de) | 2005-11-15 |
| TR200000272T2 (tr) | 2000-09-21 |
| WO1999006387A2 (en) | 1999-02-11 |
| HRP20000031A2 (en) | 2000-10-31 |
| EP1012147B1 (en) | 2005-11-02 |
| KR100343067B1 (ko) | 2002-07-03 |
| IL134193A0 (en) | 2001-04-30 |
| WO1999006387A3 (en) | 1999-04-22 |
| KR20010022362A (ko) | 2001-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25114A1 (es) | Derivados orto-sustituidos de la hidroxicumaranona como agentes antitumorales y antimetastásicos. | |
| GT199900119A (es) | Jarabe antihistaminico estabilizado. | |
| ES2220529T3 (es) | Dibenzopiranos utiles como antagonistas del receptor de los glucocorticoides, en el tratamiento de la diabetes. | |
| ES2195034T3 (es) | Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion. | |
| ES2266459T3 (es) | Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia. | |
| ES2164720T3 (es) | Derivados de piperidina como agentes anticolinergicos. | |
| ECSP088550A (es) | Nuevos compuestos que son inhibidores de erk | |
| AR002986A1 (es) | Nuevos derivados de piperazina sustituida particularmente utiles como antagonistas de receptores de taquiquinina, composiciones farmaceuticas, usosde dichos derivados y procedimiento de preparacion de los mismos. | |
| ES2055056T3 (es) | Derivados de pirimidopirimidina. | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| ES2126499B1 (es) | Coiniciadores de borato para fotopolimerizacion. | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| ES2059804T3 (es) | Procedimiento de preparacion de eteres de oxima de propenona. | |
| AR033793A1 (es) | Compuestos derivados del benceno, su utilizacion, procedimientos para su preparacion y composiciones farmaceuticas que los contienen | |
| DE60041763D1 (de) | Inhibitoren von c-jun n-terminal kinasen (jnk) | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| ES2062425T3 (es) | Piridinas, procedimientos de preparacion y medicamentos que las contienen. | |
| AR025103A1 (es) | Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos | |
| ES2043863T3 (es) | Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina. | |
| ES2189285T3 (es) | Nuevas piranonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| UY24697A1 (es) | Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa | |
| DK165691C (da) | Tricykliske aminer afledt af 2,3,5,6,7,8-hexahydronaphtho(2,3-b)furan, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem | |
| AR054414A1 (es) | Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas. | |
| ES2029879T3 (es) | Procedimiento para producir derivados de aminas sustituidas. | |
| ES2172376B1 (es) | Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20131015 |